-+ 0.00%
-+ 0.00%
-+ 0.00%

Roche Secures De Novo Approval from US FDA for Mass Spectrometry Platform with Ionify Gabapentin Assay

MT Newswires·11/16/2026 09:41:04
Listen to the news
09:41 AM EST, 11/16/2026 (MT Newswires) -- Roche (RO.SW) secured De Novo authorization from the US Food and Drug Administration for its cobas pro i 601 platform with the Ionify Gabapentin assay for mass spectrometry testing. The Swiss drugmaker said Monday it will use a Predetermined Change Control Plan approved by the FDA to expand its future clinical mass spectrometry menu on the platform to up to 22 Ionify assays. The cobas pro i 601 platform with the Ionify Gabapentin assay combines mass spectrometry with an automated, standardized workflow to provide advanced testing to routine clinical laboratories.